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Letter to the Editor
Mesenteric cysts in naevoid basal cell
carcinoma syndrome: a mimic of metastatic
disease
DOI: 10.1111/bjd.14224
DEAR EDITOR, Novel treatments that target the oncogenic hedge-
hog signalling pathway are revolutionizing the treatment of
cutaneous basal cell carcinoma (BCC) in patients with naevoid
basal cell carcinoma syndrome (NBCCS). Computed tomogra-
phy (CT) imaging screening examinations are included at base-
line in clinical trials of these agents, to establish the absence of
metastatic disease. These may reveal hidden, asymptomatic fea-
tures of this syndrome that can mimic metastatic disease, such
as mesenteric cysts as described in this report.
A 61-year-old woman with NBCCS was enrolled in a clini-
cal trial of a systemic smoothened inhibitor (vismodegib). The
patient had a history of jaw cysts requiring surgical excision
in her teens, and excision of BCCs from her fourth decade.
She had previously received multiple treatments to manage
BCCs, including topical 5-fluorouracil, photodynamic therapy,
cryotherapy, curettage and excision. Clinical examination
revealed hypertelorism, macrocephaly and multiple BCCs.
Genetic testing demonstrated a germline, heterozygous five-
nucleotide deletion in exon 3 (c.456_460del) of the patched
1 gene (PTCH1) that disrupted the reading frame, resulting in
a premature termination codon. As part of the clinical trial
protocol, she underwent CT imaging of her chest, abdomen
and pelvis. This revealed multiple mesenteric lesions, the lar-
gest of which measured 41 cm in diameter (Fig. 1a). The
differential diagnoses included mesenteric cysts and metastatic
disease. The patient proceeded to receive vismodegib on the
basis that the findings were likely to represent cystic disease.
A repeat CT after a 2-month interval demonstrated that the
largest cyst had not grown, and some smaller cysts were
reducing in size (Fig. 1b, c). However, the patient elected to
undergo laparoscopic biopsy, to exclude the remote possibility
of metastatic disease. This revealed the presence of multiple
nodules within the mesentery of the small bowel, of which
the largest lesion was excised. Histopathological examination
revealed central necrotic areas lined with dense fibrocollage-
nous tissue, suggestive of a chronic process; there was no evi-
dence of malignancy (Fig. 2a, b). A further abdominal CT
scan at 6 months demonstrated the absence of remaining
small cysts. Eight months after the start of treatment the
majority of the BCCs had resolved and the requirement for
cutaneous surgical intervention was reduced (Fig. 2c, d).
Inhibiting the hedgehog signalling pathway in patients with
NBCCS is a recent treatment strategy for BCC.1 Patients with
NBCCS frequently carry heterozygous germline mutations in
PTCH1,2 a gene that encodes a transmembrane glycoprotein,
which is crucial for the regulation of hedgehog signalling in
cells. The type of mutation does not appear to influence the
severity of the phenotype. Loss of function of the PTCH1 pro-
tein in BCC cells is thought to be the key driver that underlies
BCC formation. As PTCH1 is required for negative regulation
of smoothened, another protein in the hedgehog signalling
pathway, aberrant oncogenic hedgehog signalling ensues,
associated with BCC growth. In keeping with this model, a
landmark study by Tang et al.1 demonstrated that vismodegib,
a molecule that can compensate for loss of PTCH1 by inhibit-
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Fig 1. (a) Baseline pretreatment computed tomography (CT) image
highlighting a large mesenteric cyst: the double-headed white arrow
indicates a span of 4115 mm width. (b) A small mesenteric cyst
detected at baseline CT before treatment, indicated with a white
arrow. (c) Two months after commencing vismodegib treatment, the
same mesenteric cyst is smaller.
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ing smoothened activity, both reduced BCC burden and inhib-
ited growth of new BCCs.
Asymptomatic features of NBCCS, such as mesenteric cysts
in our patient, are likely to be detected as therapies such as
vismodegib are assessed in clinical trials and patients undergo
associated baseline imaging investigations. Mesenteric cysts,
rare in the general population, are recognized as a minor clin-
ical diagnostic criterion in NBCCS.3 In the absence of prospec-
tive studies where CT imaging is available from cohorts of
PTCH1 mutation carriers, the true frequency of mesenteric
cysts in NBCCS is unknown. Mesenteric cysts in NBCCS are
usually incidental findings on exploratory laparotomy.4 In a
series of 36 patients with NBCCS, three cases of mesenteric
cysts were identified at exploratory laparotomy.4 Uncom-
monly, patients may experience symptoms, such as colicky
abdominal pain.5 Mesenteric cysts in NBCCS are thin walled
and can range from 2 to 14 cm in diameter. The content of
mesenteric cysts is often chylous but can also be haemor-
rhagic.6 Histological examination of mesenteric cysts demon-
strates a lining consisting of fibrous tissue and smooth muscle,
often surrounded by a layer of lymphatic cells.
Mesenteric cysts and metastatic disease can be difficult to
distinguish radiologically. Serial CT imaging allows assessment
of increase in lesion size suggestive of metastatic disease over
benign cysts. Fludeoxyglucose-labelled positron emission
tomography scans also show lack of uptake in these cysts,
which may serve as a useful adjunct in case of uncertainty.7
Notably, in our case smaller mesenteric cysts (Fig. 1b)
demonstrated a reduction in size after 2 months of vismod-
egib treatment (Fig. 1c). This finding has not been previously
reported to our knowledge. Furthermore, there was an
absence of small cysts at 6 months as assessed by CT imaging.
While this preliminary finding awaits confirmation in future
studies, it may suggest that mesenteric cyst maintenance in
NBCCS is dependent on aberrant hedgehog signalling, which
is amenable to intervention by smoothened inhibitors.
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Fig 2. (a) Histology of the cyst revealed
central, amorphous, necrotic areas (white
arrows) lined with dense fibrocollagenous
tissue and chronic inflammation (black
arrows), separated by an artefactual cleft. No
evidence of neoplasia was noted
(haematoxylin and eosin, original
magnification 920). (b) A high-power view
of the cyst wall in (a) demonstrating a
lymphocytic infiltrate (original magnification
940). (c) Multiple superficial basal cell
carcinomas seen on the leg before treatment
with vismodegib and (d) at 8 months post-
treatment at the same site.
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